13F Holdings
中文EN

VALN Valneva SE IFRS

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1836564 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY3.0%
TTM net income YoY-840.6%
TTM EPS YoY-750.0%
Revenue 3-yr CAGR-21.5%
Net income 3-yr CAGR—

Margins

Gross margin38.7%
Operating margin-47.0%
Net margin-66.0%
FCF margin-32.8%
EBITDA margin—

Returns

ROE-80.2%
ROA-25.6%
ROIC (approx.)-34.5%
Asset turnover0.39x

Leverage & solvency

Liabilities / assets73.4%
Debt / equity1.69x
Current ratio2.38x
Interest coverage-1.96x

Cash quality & payout

Operating cash flow / net income0.46x
Accruals ratio-13.9%
Payout ratio—
Capex / revenue2.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: EUR FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY20212021-12-31
Income statement
Revenue174.66M169.58M153.71M361.30M348.09M
Cost of revenue107.14M98.54M100.88M324.44M187.92M
Gross profit67.52M71.04M52.84M36.86M160.17M
R&D expense85.30M74.14M59.89M104.92M173.28M
SG&A expense37.32M42.75M47.80M34.07M47.61M
Operating income-82.06M13.33M-82.09M-113.44M-61.39M
Interest expense41.90M23.98M23.32M19.05M16.96M
Pretax income-114.12M-11.49M-98.63M-144.81M-69.98M
Income tax1.07M761,0002.80M-1.54M3.45M
Net income-115.19M-12.25M-101.43M-143.28M-61.39M
EBITDA-60.31M32.92M-64.50M-92.41M-47.11M
EPS (basic)-0.68-0.08-0.73-1.24-0.75
EPS (diluted)-0.68-0.08-0.73-1.24-0.75
Weighted avg. shares (diluted)168.18M145.71M138.62M115.47M97.62M
Balance sheet
Cash & equivalents109.65M168.27M126.08M286.53M346.69M
Receivables27.81M35.20M41.65M23.91M44.01M
Inventory50.23M53.66M44.47M35.10M124.10M
Current assets222.54M299.01M262.82M424.66M585.83M
PP&E, netmay include right-of-use assets (IFRS)119.47M138.88M136.20M112.44M125.55M
Intangibles22.35M25.26M25.57M28.71M32.70M
Total assets398.84M500.03M460.06M621.34M817.35M
Current liabilities93.33M114.58M158.86M277.39M368.98M
Short-term debt17.91M20.85M44.08M11.58M7.11M
Long-term debt161.26M166.52M132.77M87.23M50.73M
Total debt179.17M187.37M176.85M98.81M57.83M
Total liabilities292.67M318.78M331.81M401.55M646.77M
Shareholders' equity106.17M181.25M128.25M219.80M170.58M
Net debt69.52M19.10M50.77M-187.72M-288.85M
Shares outstanding173.42M162.40M138.79M138.24M105.11M
Cash flow statement
Operating cash flow-52.89M-67.22M-202.74M-245.34M76.90M
Capital expenditure4.42M13.87M14.23M29.25M92.23M
Free cash flow-57.31M-81.08M-216.97M-274.59M-15.33M
Investing cash flow-1.71M76.92M-20.59M-29.05M-93.12M
Financing cash flow-621,00030.68M63.08M215.12M154.50M
Depreciation & amortization21.75M19.59M17.58M21.04M14.28M
Stock-based compensation9.53M7.97M5.11M-8.66M14.51M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.